DEVELOPING ORAL BIOLOGICS THAT ACT ON CELLS IN THE SMALL INTESTINE WITH SYSTEMIC THERAPEUTIC EFFECTS
Cells in the small intestine play a central role in governing our immune, metabolic and neurological systems.
Our first product candidates are single strains of microbes selected for defined pharmacological properties.
Our therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
About our science
Our Platform
- We have developed an integrated platform to develop oral biologics which harness the central role that cells in the small intestine play in governing our immune, metabolic and neurological systems.
- The efficiency of our platform has allowed us to produce, in a relatively short period of time, product candidates for a range of inflammatory diseases and cancer.
Our Portfolio
We currently have four product candidates: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer. We are also advancing additional oral biologics through preclinical development in other therapeutic areas.
About our portfolioEvelo is led by a team with deep experience.
Our leadership team has founded, led, and grown transformative platform biotechnology companies. Our team has also developed and commercialized medicines that have impacted many lives.
About our teamSelect News
- EVELO BIOSCIENCES TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN JUNE
Cambridge, MA - May 26, 2021 - EVELO BIOSCIENCES PRESENTS NEW PRECLINICAL DATA FOR EXTRACELLULAR VESICLE ANTI-INFLAMMATORY PRODUCT CANDIDATE EDP2939 AT THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS MEETING
Cambridge, MA - May 13, 2021 - EVELO BIOSCIENCES REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
Cambridge, MA - April 29, 2021 - EVELO BIOSCIENCES PRESENTS FURTHER POSITIVE DATA FROM PHASE 1B CLINICAL TRIAL OF EDP1815 IN ATOPIC DERMATITIS
Cambridge, MA - April 20, 2021
Select Press
- GROUNDBREAKING IMMUNOLOGY MICROBE ORAL THERAPIES, SIMBA GILL, CEO, EVELO BIOSCIENCES
Biotech 2050 Podcast - June 16, 2021 - PHARMACEUTICAL EXECUTIVE® REVEALS WINNERS OF THE 2021 EMERGING PHARMA LEADERS AWARDS
Pharmaceutical Executive® - May 11, 2021 - A BRIEF VIDEO EXPLAINING THE STRATEGIC COLLABORATION BETWEEN EVELO BIOSCIENCES AND ABDUL LATIF JAMEEL HEALTH
March 23, 2021 - CREATING THE FUTURE OF MICROBIOME-BASED THERAPIES: SIMBA GILL ON THE LONG RUN
The Long Run Podcast with Luke Timmerman - November 13, 2020
Relevant Publications
- HUMAN GUT-DERIVED COMMENSAL BACTERIA SUPPRESS CNS INFLAMMATORY AND DEMYELINATING DISEASE
Cell Reports - August 8, 2017 - MINING THE HUMAN GUT MICROBIOTA FOR IMMUNOMODULATORY ORGANISMS
Cell - February 23, 2017 - SUPPRESSION OF INFLAMMATORY ARTHRITIS BY HUMAN GUT‐DERIVED PREVOTELLA HISTICOLA IN HUMANIZED MICE
Arthritis & Rheumatology - June 23, 2016 - COMMENSAL BIFIDOBACTERIUM PROMOTES ANTITUMOR IMMUNITY AND FACILITATES ANTI–PD-L1 EFFICACY
Science - November 27, 2015
The destination for pioneers and adventurers
If you want to join an exceptional team and culture that is committed to driving profound benefits to patients and society, let us know.
Careers pageContact
620 Memorial Drive, 5th Floor
Cambridge, MA, 02139 USA
Hobday Building, The London BioScience Innovation Centre
2 Royal College Street, London, NW1 0NH, UK
For general inquiries contact:
info@evelobio.com
For media inquiries contact:
media@evelobio.com
For investor inquiries contact:
ir@evelobio.com